Potential Role for Human Interleukin-11 in Bacterial Sepsis
Human interleukin (IL)-11 was first isolated and characterized by Paul and colleagues in 1990  as one of the essential elements of the hematopoietic microenvironment. It was initially described as a hematopoietic growth factor from stromal bone marrow elements which could support the growth of a plasmacytoma cell line and had profound effects on megakaryocyte growth and development. It was subsequently shown that this is a remarkably pleiotropic cytokine with numerous physiologic attributes affecting hematopoietic and non-hematopoietic cell lines . Recent experimental evidence indicates that IL-11 possesses therapeutic properties which may prove to be beneficial in the prevention and treatment of human sepsis. This chapter will summarize the current knowledge of this important cytokine and describe its potential therapeutic role in the septic patient.
Unable to display preview. Download preview PDF.
- 8.Brandt IE, Hoffman R (1993) Interleukin-11 plays a pivotal role in the in vitro expansion of human hematopoietic progenitor and stem cells. Blood 82: 368A (Abst)Google Scholar
- 19.Elias JA, Zheng T, Einarsson O, et al (1994) Epithelial interleukin-11. Regulation by cytokines, respiratory syncytial virus and retinoic acid. J Biol Chem 269: 22 261–22 268Google Scholar
- 25.Du XX, Keller D, Goldman S, Williams DA (1992) Functional effects of interleukin-11 treatment in vivo following bone marrow transplantation (BMT) and combined modality therapy in mice. Exp Hematol 20: 807 (Abst 390)Google Scholar
- 26.Keith JC Jr, Albert LM, Ferranti TJ, et al (1995) Recombinant human interleukin-11 decreases inflammatory bowel disease in HLA-B27 transgenic rats. Annual meeting of the Am Gastroenter Ass Am Ass Study Liver Dis. San Diego, CA (Abst)Google Scholar
- 28.Opal SM, Keith JC, Schaub RG, et al (1995) Beneficial effects of recombinant human interleukin-11 in an experimental model of gram-negative sepsis in neutropenic animals. Am Soc Hematology, 37th Annual Meeting, Seattle, Washington (Abst 1980)Google Scholar
- 29.Misra BR, Ferranti TJ, Donnelly LH, Erickson JE, Keith JC Jr, Schaub RG (1995) Recombinant interleukin-11 prevents hypotension in LPS-treated anaesthesized rabbits. IBC 5th Annual Meeting of Innovative Strategies for the Prevention and Treatment of Endotoxemia in Sepsis. Philadephia, PA (Abst)Google Scholar
- 30.Chang M, Williams A, Ishizawa L, Knoppel A, Van de Ven C, Cairo MS (1994) Role of interleukin-11 during experimental group B streptococcal sepsis in neonatal rats: Prophylactic use of IL-11 improves survival and enhances platelet recovery. Blood 84(Suppl 1): Abstr 1892Google Scholar
- 31.Gordon MS, Sledge GW, Battiato L, et al (1993) The in vivo effects of subcutaneously administered recombinant human interleukin-11 in women with breast cancer. Blood 82(Suppl 1): 498a (Abst)Google Scholar
- 32.Orazi A, Cooper R, Tong J, et al (1993) Recombinant human Interleukin-11 has multiple profound effects on human hematopoiesis. Blood 82(Suppl 1): 369a (Abst)Google Scholar
- 33.Gordon MS, Battiato L, Hoffman R, et al (1993) Subcutaneously administered recombinant human Interleukin-11 prevents thrombocytopenia following chemotherapy with cyclophosphamide and doxorubicin in women with breast cancer. Blood 82(Suppl 1): 318a (Abst)Google Scholar